

MEDICINES CO /DE
Form 8-K/A
October 09, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

FORM 8 K/A
(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 5, 2013

The Medicines Company
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-31191
(Commission
File Number)

04-3324394
(IRS Employer
Identification No.)

8 Sylvan Way
Parsippany, New Jersey
(Address of Principal Executive Offices)

07054
(Zip Code)

Registrant's telephone number, including area code: (973) 290-6000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Explanatory Note

On August 7, 2013, The Medicines Company (“MDCO”) filed a Current Report on Form 8-K (the “Initial Form 8-K”) reporting the completion of its acquisition of ProFibrix B.V., a company registered in The Netherlands (“ProFibrix”). In accordance with and as permitted by Section 9.01(a)(4) of Form 8-K, MDCO is filing this amendment to the Initial Form 8-K to provide the required financial statements and pro forma financial information that were not filed with the Initial Form 8-K.

Item 9.01. Financial Statements and Exhibits

(a) Financial Statements of Businesses Acquired

The audited consolidated financial statements of ProFibrix as of and for the year ended December 31, 2012 and the period from January 29, 2004 (inception) through December 31, 2012 and accompanying notes and the report of Deloitte Accountants B.V. with respect to such financial statements, as required by this Item 9.01(a), are attached as Exhibit 99.2 hereto and incorporated herein by reference.

The unaudited financial statements of ProFibrix as of June 30, 2013 and for the six months ended June 30, 2013 and 2012 and for the period from January 29, 2004 (inception) through June 30, 2013 are also included in Exhibit 99.3 and are incorporated herein by reference .

(b) Pro Forma Financial Information

The following unaudited pro forma combined financial statements, together with related explanatory notes, showing the pro forma effect on MDCO's financial statements of MDCO's acquisition of ProFibrix and other related pro forma events are attached hereto as Exhibit 99.3 and are incorporated herein by reference: (i) balance sheet as of June 30, 2013 and (ii) statements of operations for the six months ended June 30, 2013 and 2012.

(d) Exhibits

2.1*† Share Purchase Agreement, dated June 4, 2013, by and among the Company, ProFibrix, the equityholders of ProFibrix, certain members of the management team of ProFibrix in their capacities as warrantors of certain information in the Purchase Agreement, the holders of options to acquire equity interests in ProFibrix and the Representative.

23.1 Consent of Deloitte Accountants B.V. Independent Auditors for ProFibrix

99.1 Press Release dated August 5, 2013, announcing completion of the acquisition of ProFibrix (filed as exhibit 99.1 to MDCO’s current report on Form 8-K, filed on August 7, 2013, and incorporated herein by reference)

99.2 Audited financial statements of ProFibrix as of and for the year ended December 31, 2012 and the period from January 29, 2004 (inception) through December 31, 2012.

99.3 Unaudited interim financial statements of ProFibrix as of June 30, 2013 and for the six months ended June 30, 2013 and 2012 and for the period from January 29, 2004 (date of inception) through June 30, 2013.

99.4 Unaudited pro forma combined financial statements of MDCO as of and for the six months ended June 30, 2013 and year ended December 31, 2012.

* Schedules (and similar attachments) have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally copies of any of the omitted schedules (or similar attachments) to the Securities and Exchange Commission upon request.

† Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE MEDICINES COMPANY

Date: October 9, 2013

By: /s/ Paul M. Antinori

Paul M. Antinori

Senior Vice President and General Counsel

Exhibit Index

Exhibit No.	Description
2.1*†	Share Purchase Agreement, dated June 4, 2013, by and among the Company, ProFibrix, the equityholders of ProFibrix, certain members of the management team of ProFibrix in their capacities as warrantors of certain information in the Purchase Agreement, the holders of options to acquire equity interests in ProFibrix and the Representative.
23.1	Consent of Deloitte Accountants B.V. Independent Auditors for ProFibrix
99.1	Press Release dated August 5, 2013, announcing completion of the acquisition of ProFibrix (filed as exhibit 99.1 to MDCO's current report on Form 8-K, filed on August 7, 2013, and incorporated herein by reference)
99.2	Audited financial statements of ProFibrix B.V. as of and for the year ended December 31, 2012 and the period from January 29, 2004 (inception) through December 31, 2012.
99.3	Unaudited interim financial statements of ProFibrix as of June 30, 2013 and for the six months ended June 30, 2013 and 2012 and for the period from January 29, 2004 (date of inception) through June 30, 2013.
99.4	Unaudited pro forma combined financial statements of MDCO as of and for the six months ended June 30, 2013 and year ended December 31, 2012

* Schedules (and similar attachments) have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally copies of any of the omitted schedules (or similar attachments) to the Securities and Exchange Commission upon request.

† Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.